BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, May 25, 2025
Breaking News: 100 days of uncertainty
See today's BioWorld Science
Home
» Gilead Sciences discloses new compounds for Zika virus infection
To read the full story,
subscribe
or
sign in
.
Infection
Gilead Sciences discloses new compounds for Zika virus infection
Dec. 15, 2022
Gilead Sciences Inc. has presented tetracyclic compounds reported to be useful for the treatment of Zika virus infection.
BioWorld Science
Infection
Patents
